糖尿病肾病与MCP-1、SICAM-1的相关性及辛伐他汀对其干预治疗的作用  

Dependablity between diabetic nephropathy and the expressions of MCP-l and SICAM-l and the treatment of simvastatin

作　　者：李彦华[1] 宋剑[2] 张淑芳[1] 徐延平[1] 章莉[3] 

机构地区：[1]济南市第一人民医院,山东济南250011 [2]山东大学齐鲁医院 [3]济南市历下区人民医院

出　　处：《山东医药》2008年第38期8-9,共2页Shandong Medical Journal

基　　金：济南市卫生局科技项目(2007-38)

摘　　要：目的探讨糖尿病肾病(DN)与血清单核细胞趋化蛋白1(MCP-l)、可溶性细胞间黏附分子1(sICAM-l)的相关性,以及辛伐他汀干预治疗对早期DN的作用。方法将60例DN患者随机分为对照组和辛伐他汀治疗组,治疗16周后,观察两组血清MCP-l、sICAM-l及尿白蛋白排泄率(UAER)变化,评价辛伐他汀对患者肾脏的保护作用。结果与对照组比较,治疗组血清MCP-1、sICAM-1及UAER均明显降低(P均<0.05)。结论辛伐他汀对早期DN患者有肾脏保护作用,能延缓其进展为终末期肾病。Objective To research the dependability between blood serum MCP-1 and SICAM-1 level and diabetes nephropathy relevance. Methods 60 diabetes nephropathy patients were divided into control groups and simvastatin treatment group randomly. After 16-week treatment, urine albumin excretion rate and MCP-1, SICAM-1 level changes were observed, and renal protective effect of simvastatin was evaluated. Results Serum MCP-1, SICAM-1 and UAER levels in treatment group were significantly lower than control group（P 〈 0.05）. Conclusions Simvastatin can protect the kidney, and delay the progression of early diabetic nephropathy.

关 键 词：糖尿病 肾性 辛伐他汀 单核细胞趋化蛋白 细胞间黏附分子 尿白蛋白排泄 

分 类 号：R587.2[医药卫生—内分泌]